SLC5A2 and coronary artery disorder: Glacobellis found that when glucagon-like peptide-1 (GLP-1) and sodium-glucose cotransporter 2 (SGLT2) reduced left atrial and coronary EAT thickness, EAT inflammation was decreased with a concomitant increase in fatty acid oxidation, preventing atrial fibrillation and coronary artery disease, especially in patients with high BMI [11].